Literature DB >> 27000188

[Myasthenia gravis].

J Schodrowski1, M Seipelt1, I Adibi-Sedeh1, C Eienbröker1, B Tackenberg2.   

Abstract

Myasthenia gravis is an autoimmune disease, which leads to load-dependent weakness of voluntary skeletal muscles with recovery of function after resting. The disease is caused by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptors (AChR) leading to a reduction of neuromuscular transmission. Muscles and nerves are not affected. Disorders of the thymus play a role in the pathogenesis of AChR antibody-positive myasthenia. The clinical symptoms include exercise-induced fatigue either of the ocular muscles alone (ocular myasthenia) or striated skeletal muscle and the ocular, facial and bulbar musculature (generalized myasthenia). Treatment of myasthenia gravis involves administration of acetylcholine esterase inhibitors and immunosuppressive drugs. A myasthenic crisis is characterized by life-threatening complications with severe weakness, swallowing difficulties and respiratory failure, which requires intensive care treatment.

Entities:  

Keywords:  Acetylcholine; Acetylcholine esterase inhibitors; Autoimmune diseases; Neuromuscular diseases; Thymus gland

Mesh:

Substances:

Year:  2016        PMID: 27000188     DOI: 10.1007/s00108-016-0035-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.

Authors:  Steven Vernino; Diva R Salomao; Thomas M Habermann; Brian P O'Neill
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

Review 2.  The immunopathogenesis of myasthenia gravis.

Authors:  Norbert Sommer; Björn Tackenberg; Reinhard Hohlfeld
Journal:  Handb Clin Neurol       Date:  2008

Review 3.  CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis.

Authors:  Bianca M Conti-Fine; Monica Milani; Wei Wang
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

4.  Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.

Authors:  F Hanisch; M Wendt; S Zierz
Journal:  Eur J Med Res       Date:  2009-08-12       Impact factor: 2.175

Review 5.  Cellular mechanisms in inflammatory myopathies.

Authors:  R Hohlfeld; N Goebels; A G Engel
Journal:  Baillieres Clin Neurol       Date:  1993-11

Review 6.  Thymectomy in the management of myasthenia gravis.

Authors:  Alfred Jaretzki; Kenneth M Steinglass; Joshua R Sonett
Journal:  Semin Neurol       Date:  2004-03       Impact factor: 3.420

7.  Thymectomy in myasthenia with pure ocular symptoms.

Authors:  F Schumm; H Wiethölter; A Fateh-Moghadam; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

Review 8.  Bone densitometry, steroids and osteoporosis.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-11       Impact factor: 2.894

9.  Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches.

Authors:  Dan M Meyer; Morley A Herbert; Nasin C Sobhani; Paul Tavakolian; Andrea Duncan; Michelle Bruns; Kevin Korngut; Janet Williams; Syma L Prince; L Huber; Gil I Wolfe; Michael J Mack
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330

10.  A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.

Authors:  Jeannine M Heckmann; Amanullah Rawoot; Kathleen Bateman; Rudi Renison; Motasim Badri
Journal:  BMC Neurol       Date:  2011-08-05       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.